

## REFERENCES

- Ahmed, A.A., Etemadmoghadam, D., Temple, J., Lynch, A.G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., Defazio, A. and Bowtell, D., 2010. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *The Journal of pathology*, 221(1), pp.49-56.
- Chiaramonte, R., Colombo, M., Bulfamante, G., Falleni, M., Tosi, D., Garavelli, S., De Simone, D., Vigolo, E., Todoerti, K., Neri, A. and Platonova, N., 2015. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1 $\alpha$  chemokine system. *The international journal of biochemistry & cell biology*, 66, pp.134-140.
- Choi, J.H., Wong, A.S., Huang, H.F. and Leung, P.C., 2007. Gonadotropins and ovarian cancer. *Endocrine reviews*, 28(4), pp.440-461.
- Elvert, G., Kappel, A., Heidenreich, R., Englmeier, U., Lanz, S., Acker, T., Rauter, M., Plate, K., Sieweke, M., Breier, G. and Flamme, I., 2003. Cooperative interaction of hypoxia-inducible factor-2 $\alpha$  (HIF-2 $\alpha$ ) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). *Journal of Biological Chemistry*, 278(9), pp.7520-7530.
- Fathalla, M.F., 2013. Incessant ovulation and ovarian cancer—a hypothesis revisited. *Facts, views & vision in ObGyn*, 5(4), p.292.
- Goff, B.A., Mandel, L., Muntz, H.G. and Melancon, C.H., 2000. Ovarian carcinoma diagnosis. *Cancer*, 89(10), pp.2068-2075.
- Ho, C.L., Kurman, R.J., Dehari, R., Wang, T.L. and Shih, I.M., 2004. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. *Cancer research*, 64(19), pp.6915-6918.
- Holderfield, M.T. and Hughes, C.C., 2008. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor- $\beta$  in vascular morphogenesis. *Circulation research*, 102(6), pp.637-652.
- Hopfer, O., Zwahlen, D., Fey, M.F. and Aebi, S., 2005. The Notch pathway in ovarian carcinomas and adenomas. *British journal of cancer*, 93(6), pp.709-718.
- Hu, C. and Jiang, X., 2016. Role of NRP-1 in VEGF-VEGFR2-independent tumorigenesis. *Targeted oncology*, 11(4), pp.501-505.
- Hu, W., Lu, C., Dong, H.H., Huang, J., Shen, D.Y., Stone, R.L., Nick, A.M., Shahzad, M.M., Mora, E., Jennings, N.B. and Lee, S.J., 2011. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian carcinoma. *Cancer research*, 71(18), pp.6030-6039.

- Jakobsson, L., Bentley, K. and Gerhardt, H., 2009, 'VEGFRs and Notch: a dynamic collaboration in vascular patterning', *Biochemical Society Transactions* vol.37, no.6, pp.1233-36.
- Kofler, N.M., Shawber, C.J., Kangsamaksin, T., Reed, H.O., Galatioto, J. and Kitajewski, J., 2011. Notch signaling in developmental and tumor angiogenesis. *Genes & cancer*, 2(12), pp.1106-1116.
- Koshiyama, M., Matsumura, N. and Konishi, I., 2014. Recent concepts of ovarian carcinogenesis: type I and type II. *BioMed research international*, 2014.
- Kumar, V., Abbas, A.K. and Aster, J.C., 2017. *Robbins Basic Pathology E-Book*. Elsevier Health Sciences.
- Lin, Y.C., Chao, T.Y., Yeh, C.T., Roffler, S.R., Kannagi, R. and Yang, R.B., 2016. Endothelial SCUBE2 interacts with VEGFR2 and regulates VEGF-induced angiogenesis. *Arteriosclerosis, thrombosis, and vascular biology*, pp.ATVBAHA-116.
- National Cancer Institute. (2017). NCI Dictionary of Cancer Terms. [online] Available at: <http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742>
- Ovarian Cancer Research Fund Alliance, 2017, *Statistics - Ovarian Cancer Research Fund Alliance*. [online] Available at: <https://ocrfa.org/patients/about-ovarian-cancer/statistics>
- Penson, R.T., Moore, K.N., Fleming, G.F., Braly, P.S., Schimp, V.L., Nguyen, H., Matulonis, U., Banerjee, S.N., Haluska, P., Gore, M.E. and Bodurka, D.C., 2012. A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162).
- Shih, I.M. and Kurman, R.J., 2004. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. *The American journal of pathology*, 164(5), pp.1511-1518.
- Smith, E.R. and Xu, X.X., 2008. Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion. *The lancet oncology*, 9(11), pp.1108-1111.
- Spannuth, W.A., Nick, A.M., Jennings, N.B., Armaiz-Pena, G.N., Mangala, L.S., Danes, C.G., Lin, Y.G., Merritt, W.M., Thaker, P.H., Kamat, A.A. and Han, L.Y., 2009. Functional significance of VEGFR-2 on ovarian cancer cells. *International journal of cancer*, 124(5), pp.1045-1053.
- Tsakonas, S., Rand, M.D. and Lake, R.J., 1999. Notch signaling: cell fate control and signal integration in development. *Science*, 284(5415), pp.770-776.

WHO, 2017 [online] Available at: [http://www.who.int/cancer/country-profiles/idn\\_en.pdf](http://www.who.int/cancer/country-profiles/idn_en.pdf)

Youssef, H.E.S.M., Abo-Azma, N.E.E. and Megahed, E.M.E., 2015. Correlation of hypoxia-inducible factor-1 alpha (HIF-1 $\alpha$ ) and vascular endothelial growth factor (VEGF) expressions with clinico-pathological features of oral squamous cell carcinoma (OSCC). Tanta Dental Journal, 12, pp.S1-S14.